...) and Alzheimer’s disease (AD), but the specific aspects that are affected, their neuropathology, and potential value for classification modeling is unknown. The current study examined if multiple measures of motor strength, dexterity, and speed are affected in MCI and AD, related to AD biomarkers, and are able...

...Jesús Garcia Castro; Helena Méndez del Sol; Olaia Rodríguez Fraga; María Hernández Barral; Soledad Serrano López; Ana Frank García; Ángel Martín Montes Introduction: Cerebrospinal fluid (CSF) biomarker quantification provides physicians with a reliable diagnosis of Alzheimer’s disease (AD). However...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Parkinson’s disease Cystatin-C Neurofilament light chain Progression Biomarkers Parkinson’s disease (PD...

... of the disease still requires postmortem examination. Identifying and validating biomarkers are essential steps toward improving clinical diagnosis and accelerating the search for therapeutic drugs to ameliorate disease symptoms. Until recently, statistical analysis of multicohort longitudinal studies...

... fluid (CSF) biomarkers - 42-amino-acid amyloid-β (Aβ 42 ), total tau and phosphorylated tau (p-tau) - has demonstrated high validity for detecting AD neuropathological changes. However, their prognostic utility to predict the onset of dementia in predementia subjects is still questioned. We aimed...

...R.S. Osorio; E. Pirraglia; T. Gumb; J. Mantua; I. Ayappa; S. Williams; L. Mosconi; L. Glodzik; M.J. de Leon Background: The pathophysiological process of Alzheimer's disease (AD) begins many years before the emergence of clinical symptoms (preclinical AD). A hypothetical biomarker progression...

... and Aβ and with studies testing these proteins as disease biomarkers, hence favouring the eventual testing of therapeutic strategies targeting these proteins in PD. Here, we review the available evidence on the topic, focusing particularly on studies conducted using archival material from the Queen...

... E2012. Conclusions: The results presented add to the current knowledge on APP processing and that Aβ isoforms can be used as novel biomarkers to monitor anti-Aβ treatments in clinical trials and may be valuable for making a go/no go decision for large and expensive phase 2 or 3 clinical trials...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Spinocerebellar ataxia Periodic leg movements Sleep disorders REM sleep, without atonia Biomarkers Diseases Original Paper Neurodegenerative Dis 2011;8:447 454 DOI...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Alzheimer’s disease Biomarkers Pharmacogenomics Apolipoprotein E Diseases...

... or vitamin E. The results support the investigation of biomarkers of antioxidant status as risk factors for cognitive decline in MCI. National Institutes of Health (NIH) 10.13039/100000002 Diseases Original Paper Neurodegenerative Dis 2009;6:23 28 DOI: 10.1159/000170883 Received: February 19...

... biomarkers to identify incipient AD. Objective: The aim of the present study was to investigate if the AD-associated Aβ peptide pattern recently found in cerebrospinal fluid (CSF) could discriminate between patients with incipient AD and those with stable mild cognitive impairment (MCI) by analyzing CSF from...

... cognitive impairment Isoprostanes Oxidative stress Biomarkers Abstract Background: Oxidative damage is implicated in the pathophysiology of Alzheimer s disease (AD). F2-isoprostane is a marker of lipid peroxidation which is elevated in AD CSF. Plasma F2-isoprostane has been proposed as a diagnostic...